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A B S T R A C T
The global cosmetic industry is constantly searching for new ingredients with multifunctional properties. In this
context, phenolic compounds (p-hydroxybenzoic, p-coumaric, and protocatechuic acids), cinnamic acid and
ergosterol were evaluated for their anti-inflammatory, anti-tyrosinase and antimicrobial activities, and there-
after microencapsulated by the atomization/coagulation technique. After characterization (morphology, particle
size distribution and encapsulation efficiency), the microencapsulated compounds were incorporated into a
semi-solid base cream and their performance evaluated comparatively with the use of the free forms. The cos-
meceutical formulations were checked regarding the presence of the bioactive compounds by HPLC-DAD, and
for their physicochemical properties (colour and pH). The obtained results demonstrated the anti-tyrosinase,
anti-inflammatory and antimicrobial activities of the individual compounds that, after incorporation, have
shown a decreasing pattern along time. On the contrary, the formulations incorporating the microencapsulated
bioactive compounds gave rise to a gradual release, ensuring bioactivity maintenance. These results underline
the advantage of using microencapsulation to preserve and ensure the controlled release of bioactive species in
cosmeceutical formulations.
1. Introduction
Skin care formulations are designed to exert multifunctional prop-
erties, thus increasing the industrial interest of using bioactive agents
such as phenolic compounds, vitamins, terpenoids, steroids and poly-
unsaturated fatty acids from natural sources [1]. The use of bioactive
compounds as cosmetic ingredients has generated a new product's trend
known as “Cosmeceuticals”, which is still unfamiliar to most of the
global consumers. Cosmeceuticals are formulated with biologically ac-
tive ingredients, that exert a medical drug-like benefit on the skin [2].
The skin is equipped with intrinsic enzymatic antioxidants which
neutralize free radicals and repair oxidative damage. Continuous oxi-
dative processes in the body lowers the activities of these antioxidants
by promoting the skin ageing process [3]. Among the different classes
of bioactive compounds used in skin care products, compounds that
display antioxidant activity seem to be the most required due to their
action on several cell signal transduction pathways related to ageing,
inflammation, hyperpigmentation and extracellular matrix degradation
[3–5].
Phenolic acids and related compounds, are a group of secondary
metabolites from fungi and plants [6]. These compounds are known for
their antioxidant, anti-collagenase, anti-inflammatory, antimicrobial
and anti-tyrosinase activities, as well as for the ultraviolet (UV) pro-
tective effects making them appropriate multifunctional ingredients to
be used in the design of topical formulations [1,7]. On the other hand,
ergosterol is a precursor of vitamin D commonly found in fungi and
protozoans' membranes. Numerous reports have suggested that ergos-
terol, ergosterol peroxide, ergostatrien-3β-ol, hericirine, botulin, tra-
metenolic acid and other steroidal compounds display biological
properties such as antitumor [8], antioxidant [9] anti-inflammatory
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[10] and anti-tyrosinase activities [11]. Nevertheless, their use as
bioactive ingredients in cosmeceutical formulations has not been yet
fully established. Besides being already used in cosmetics due to their
effectiveness in suppressing the severity of inflammatory diseases,
psoriasis and eczema [7,12], sterols still need to be further studied to
fully explore their cosmeceutical potential.
The use of these compounds in cosmeceutical formulations still face
constraints related with instability, sensitivity to pH and temperature,
easy degradation and low efficacy. To overcome these issues, recent
trends pointed out the use of polymeric carriers such as chitosan, al-
ginate and polylactic acids to protect (encapsulate) bioactive com-
pounds [3,13]. Comparatively with ergosterol, and despite the fact that
phenolic acids potential as cosmetic ingredients are well reported, very
few studies were conducted to describe the incorporation of these
molecules into cosmetics (e.g. semi solid base formulations), namely to
evaluate their bioactive properties, stability, and maintenance over an
extended period of time.
The present study intends to evaluate the anti-inflammatory, anti-
microbial and anti-tyrosinase activities of p-hydroxybenzoic, p-cou-
maric, protocatechuic and cinnamic acids, and ergosterol. Based on the
exhibited bioactivity, and interest to be used in cosmeceuticals for-
mulations, these compounds were microencapsulated using the atomi-
zation/coagulation method with calcium alginate as the matrix mate-
rial. The produced microspheres were fully characterised and tested
against the use of the non-encapsulated forms (free compounds) in a
base cosmetic (semi-solid formulation). Each produced formulation was
submitted to bioactivity evaluation over a period of 6months to as-
certain stability and monitor the in vitro release of compounds re-
sponsible for the effect. Additionally, target compounds (phenolic acids,
cinnamic acid, and ergosterol), incorporated in its free form were
monitored using the HPLC-DAD technique.
2. Materials and methods
2.1. Standards and reagents
Acetonitrile 99.9% was of high-performance liquid chromatography
(HPLC) grade from Lab-Scan (Lisbon, Portugal), methanol was of ana-
lytical grade and supplied by Pronalab (Lisbon, Portugal). Dulbecco's
modified Eagle's minimum essential medium (DMEM), p-hydro-
xybenzoic, p-coumaric, protocatechuic and cinnamic acids, fetal bovine
serum (FBS), penicillin, streptomycin, Griess reagent system (Promega),
DIMETHYL sulphoxide (DMSO), lipopolysaccharide (LPS), 3,4-dihy-
droxy-L-phenylalanine (L-DOPA) and mushroom tyrosinase enzyme
were obtained from Sigma-Aldrich Co. (Saint Louis, MO, USA). Sodium
alginate was provided by Fluka Chemie (USA), Calcium chloride and
Tween 80 by Panreac (Spain). The culture media Muller Hinton broth
(MHB) and Tryptic Soy Broth (TSB) were obtained from Biomerieux
(Marcy l'Etoile, France). Blood agar with 7% sheep blood and
MacConkey agar plates were purchased from Biomerieux Marcy l'Etoile,
France. The dye p-iodonitrotetrazolium chloride (INT) was purchased
from Sigma-Aldrich (Spruce Street; St. Louis, MO, USA) and was used as
a microbial growth indicator.
2.2. Evaluation of bioactive properties of individual compounds
2.2.1. Anti-inflammatory activity
The evaluation of the anti-inflammatory activity was carried out
according to the procedure reported by Taofiq et al. [14]. Briefly,
mouse macrophage-like cell line RAW264.7 was cultured in DMEM
medium supplemented with 10% heat-inactivated fetal bovine serum,
glutamine, and antibiotics at 37 °C under 5% CO2, in humidified air. For
each experiment, cells were detached with a cell scraper. A cell density
of 5×105 cells/mL was used, and the proportion of dead cells was<
5%, according to Trypan blue dye exclusion test. Cells were seeded in
96-well plates at 150,000 cells/well and allowed do attach to the plate
overnight. Then, cells were treated with different concentrations of
each extract for 1 h, and further stimulated with LPS (1 μg/mL) for 18 h.
Dexamethasone (50 μM) was used as a positive control. The effect of all
the tested samples in the absence of LPS was evaluated to observe
possible induced changes in nitric oxide (NO) basal levels. Both com-
pounds and LPS were dissolved in supplemented DMEM. For inhibition
of NO, compounds were dissolved in 50% DMSO and further submitted
to sequential dilutions (400 to 50 μg/mL) in order to determine the
effective concentration necessary to reveal anti-inflammatory activity.
Griess Reagent System kit which contains sulphanilamide, N-(1-nap-
thyl) ethylenediamine hydrochloride (NED) and nitrite solutions was
used. A reference curve of nitrite (sodium nitrite 100 μM to 1.6 μM;
y= 0.0066x+ 0.1349; R2=0.9986) was prepared and the cell culture
supernatant (100 μL) was transferred to the plate and mixed with sul-
phanilamide and NED solutions, 5–10min each, at room temperature.
The NO production was determined by measuring the absorbance at
540 nm (microplate reader ELX800 Biotek), and by comparison with
the standard calibration curve.
2.2.2. Antimicrobial activity
2.2.2.1. Selected microbial strains. The microbial strains used in the
present work were clinical isolates obtained from patients hospitalized
in various departments at the Hospital Center of Trás-os-Montes and
Alto Douro (Vila Real, Portugal). Two Gram-negative bacteria
(Escherichia coli and Proteus mirabilis (isolated from urine), and three
Gram-positive bacteria (Enterococcus faecalis (isolated from urine),
methicillin-sensitive Staphylococcus aureus (MSSA) (isolated from
wound exudate), and methicillin-resistant Staphylococcus aureus
(MRSA) (isolated from expectoration)), and a yeast, Candida albicans
(isolated from urine) were tested. All the microorganisms were
incubated in appropriate fresh medium for 48 h and kept in the oven
at 37 °C before analysis in order to maintain the exponential growth
phase.
2.2.2.2. Characterization of the antibiotic susceptibility of the microbial
strains. The microorganism identification and respective susceptibility
to antibiotics was evaluated using MicroScan panels (MicroScan®;
Siemens Medical Solutions Diagnostics, West Sacramento, CA, USA)
by the microdilution method. The results were analysed following the
Interpretive Breakpoints as recommended by the Clinical and
Laboratory Standards Institute (CLSI) [15]; Committee of
L'Antibiogramme de la Société Française de Microbiologie (CA-SFM)
[16]; and the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [17] (Tables S1, S2, Supplementary materials).
2.2.2.3. Determination of the minimal inhibitory concentration
(MIC). Each compound was dissolved in 25% DMSO to prepare a
stock solution of at 25mg/mL from which several dilutions were
performed to establish a concentration test range between 0.078 and
5mg/mL. The determination of the minimal inhibitory concentration
(MIC) was performed by the microdilution method and the rapid p-
iodonitrotetrazolium chloride (INT) colourimetric assay, as also
reported by Taofiq, Heleno et al. [18]. Initially, 100 μL of the stock
solution, 400 μL of medium TSB or MHB, according to the bacteria
requirements, were added making a solution of 5mg/mL at 5% DMSO.
Then, 190 μL of this solution was added to each well of the 96-well
microplate, and therefore submitted to successive dilutions over the
wells containing 90 μL of MHB or TSB media. Then, 10 μL of inoculum
(1.5× 108 CFU/mL) were added to all the microplate wells. Two
negative controls were prepared (one with MHB/TSB 5% DMSO, and
another one with the tested compounds and media). A positive control
with MHB/TSB medium at 5% DMSO and the inoculum was used as
positive control. Regarding the antibiotic controls, colistin was used for
the Gram-negative bacteria, vancomycin for the Gram-positive bacteria,
and fluconazole for C. albicans, at a concentration based on the obtained
MIC levels (Table S2, Supplementary materials). The plates were then
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incubated at 37 °C, for 24 h, in an oven (Jouan, Berlin, Germany) and
the MIC values determined after adding INT (0.2 mg/mL, 40 μL) and
after incubation at 37 °C for 30min. Viable microorganisms reduced the
yellow dye to a pink colour. MIC was defined as the lowest compound
concentration that prevented this change, thus showing the inhibition
of the microbial growth.
2.2.3. Anti-tyrosinase activity
The tyrosinase inhibition assay was performed using L-DOPA as
substrate according to the procedure described by Taofiq, Heleno et al.
[18]. The assay was carried out in triplicate in a 96-well microplate and
absorbance was measured at 475 nm. Compounds and ascorbic acid
used as control were dissolved in 50% DMSO. Each well contained
40 μL of individual compound with 80 μL of phosphate buffer (0.1M,
pH 6.8), 40 μL of tyrosinase enzyme (60 units/mL), and 40 μL of L-
DOPA (3.5 mM). The mixture was further incubated for 10min at 37 °C,
and the absorbance (A) was measured at 475 nm using a microplate
reader (ELX800 Biotek). Each sample was accompanied by a blank
containing all the components except L-DOPA. The results were com-
pared with a control consisting of 50% DMSO replacing the sample. The
percentage of tyrosinase inhibition was calculated as follows: [(Acon-
trol−Asample) / Acontrol]× 100.
2.3. Microencapsulation of the individual compounds
2.3.1. Microencapsulation procedure
The atomization/coagulation technique was employed to micro-
encapsulate the compounds according to the procedure previously de-
scribed by Caleja et al. [19], with slight modifications. Sodium alginate,
in combination with calcium chloride (CaCl2), to promote alginate ge-
lation, was used. The microspheres were produced as follows: 100mg of
the extract was suspended in 20mL of distilled water in the presence of
100mg of tween 80 as surfactant. The mixture was then homogenized
for 20min using a Unidrive X100 homogenizer (Ingenieurbüro CAT,
Germany). Thereafter, 400mg of sodium alginate were added to the
suspension, being this mixture kept under stirring until complete dis-
solution of alginate was achieved. The produced mixture was atomized
in a NISCO Var J30 system (Zurich, Switzerland) at a flow rate of
0.3 mL/min and a nitrogen pressure of 100mbar, and coagulation
performed using 250mL of a CaCl2 solution (concentration of 4% (w/
v)) over a time-period of 4 h. The produced microspheres were then
recovered by filtration under reduced pressure, washed twice with
distilled water, lyophilized and stored in dark conditions at 4 °C. For
easy identification of the samples, the following codes were assigned to
each type of microparticles, denoting the contained ingredient: A -
empty microparticles B - p-hydroxycinnamic acid, C - p-coumaric acid,
D - cinnamic acid, E - protocatechuic acid, F - Ergosterol.
2.3.2. Microencapsulation efficiency, yield and load
2.3.2.1. Encapsulation efficiency (EE %). This parameter measures the
ability of the encapsulating material to properly encapsulate the
bioactive ingredient. It translates the amount effectively
microencapsulated, which can be achieved by measuring the amount
that has not been encapsulated (in the present case, the cumulative
amount of the compound present in the coagulation solution and in the
first washing solution), with respect to the theoretical amount used in
the formulation (Eq. (1)). Quantification of the respective compound
was done by HPLC coupled to a photodiode array detector (PDA) [20].
= ×weight of the encapsulated bioactive
weight of bioactive used in the formulation
EE (%) 100 (1)
2.3.2.2. Encapsulation yield (EY %). This parameter relates the total
amount of produced microcapsules with the amount of atomized
material (Eq. (2)).
= ×weight of produced micropheres
weight of the atomized formulation
EY (%) 100 (2)
2.3.2.3. Encapsulation load (EL %). This parameter measures the
bioactive content (%, w/w) present in the produced microspheres and
can be calculated using Eq. (3).
= ×weight of the encapsulated bioactive
weight of the produced micropheres
EL (%) 100 (3)
2.3.3. Microcapsules characterization
Microspheres were analysed by optical microscopy (OM) using a
Nikon Eclipse 50i microscope (Tokyo, Japan) equipped with a Nikon
Digital Sight camera and NIS Elements software for data acquisition.
OM analysis was applied to assess the size and morphology of the mi-
crospheres right after the atomization and during the coagulation stage.
This analysis can be also useful to check the presence of the extract
inside the microspheres.
The particle size distributions were determined by laser diffraction
using a Malvern Mastersizer 3000 laser equipped with a Hydro MV
dispersion unit (Malvern, UK). Data was obtained and treated with
Mastersizer software version 3.10. Water was used as the sample dis-
persion medium. Five measurements were made to ensure reproduci-
bility, and the results were expressed in volume and number, being
particle size results expressed as the 10%, 50% and 90% percentiles. All
the residual values were< 1%. The span of the particle size distribu-
tion, based on the volume distribution, was also determined using the
expression (Dv90−Dv10) / Dv50 [21].
2.4. Incorporation of the free and microencapsulated compounds into the
cosmetic formulations
A cosmetic base cream with light colour, free from fragrances,
colourants, parabens, mineral oils, sodium lauryl sulphate (SLS), pro-
pylene glycol, and ethoxylates, purchased from Fagron Iberica S.A.U.
(Barcelona, Spain) was used. According to the technical data available,
this formulation has been certified to be safe by the US Food and Drug
Administration (FDA), Regulation (EC) No 1907/2006—REACH and
the National Health Surveillance Agency (ANVISA) of Brazil. To cover
all the evaluated bioactive properties, the base creams were in-
corporated at a content 2.5-fold the EC50 and MIC values, which cor-
responded to a scale of 7mg of individual compound and 63mg of
microspheres per gram of base cream. A higher incorporation was not
viable due to the significant physicochemical changes associated to the
adding of the microspheres to the base cream. The individual com-
pounds, or the prepared microspheres, were incorporated into the base
cream, with homogenization achieved by stirring. Periodically
(0months, 3 months and 6months), samples were analysed to de-
termine their bioactive properties and physicochemical changes over a
6-month time period. For the determination of the bioactive properties,
stock solutions were prepared from the developed formulations by
dissolution in a 50% DMSO solution at a concentration of 100mg/mL
for anti-tyrosinase and anti-inflammatory activities evaluation. For the
antimicrobial activity evaluation, the samples were prepared in 10%
DMSO at 800mg/mL and kept at 37 °C to enable formulations dis-
solution.
For easy identification of the samples, each formulation was la-
belled as follows: i) Cosmeceutical formulations incorporated with free
individual compounds: CFHA - p-hydroxybenzoic acid, CFCoA - p-cou-
maric acid, CFCA - cinnamic acid, CFPA - protocatechuic acid, CFE -
ergosterol; ii) cosmeceutical formulations incorporated with micro-
encapsulated compounds: CFEM - empty microspheres (control),
CFMHA - microspheres with p-hydroxybenzoic acid, CFMCoA - micro-
spheres with p-coumaric acid, CFMCA - microspheres with cinnamic
acid, CFMPA - microspheres with protocatechuic acid, CFME -
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microspheres with ergosterol. For all the assays a negative control was
analysed with base cream (BA).
2.5. Chemical characterization of the cosmeceutical formulations
The cream formulations containing the free compounds were ex-
tracted with methanol for 30min, filtered, and dried in a rotary eva-
porator (Büchi R-210, Flawil, Switzerland). For phenolic acids analysis,
the samples were dissolved in a water:methanol mixture (80:20 v/v),
filtered through a 0.22 μm nylon disposable filter and then injected in a
Shimadzu 20A series ultra-fast liquid chromatograph (UFLC, Shimadzu
Corporation, Kyoto, Japan). For ergosterol analysis, the sample was
dissolved in methanol, filtered and further injected in the HPLC-UV
(Knauer, Smartline system 1000, Berlin, Germany. The individual
compounds were quantified using calibration curves obtained from
commercial standards, namely: protocatechuic acid (y= 164,741x;
R2= 0.999), p-hydroxybenzoic acid (y=113,523x; R2= 0.999),
p-coumaric acid (y= 433,521x; R2= 0.998), cinnamic acid
(y=583,527x; R2= 0.998), ergosterol (y= 0.71727x, R2= 0.996).
Clarity 2.4 Software (DataApex) was employed for data analysis. The
results were expressed as μg per g of cream and mg per g of cream for
phenolic acids and ergosterol, respectively.
2.6. Physicochemical parameters of the cosmeceutical formulations
2.6.1. Colour measurement
The colour of cosmeceutical formulations was measured using a
colourimeter (model CR-400, Konica Minolta Sensing Inc., Tokyo,
Japan) that has been calibrated against a standard white tile [22]. The
colour was measured using the L*a*b* system where L⁎ is a measure of
the lightness, a⁎ is a measure of the greenness/redness while b⁎ is a
measure of the blueness/yellowness. The colour of each sample was
measured in three different points, and the average considered the true
colour value. Colour space values were registered using the data soft-
ware “Spectra Magic Nx” (version CM-S100W 2.03.0006).
2.6.2. pH measurement
The pH of cosmeceutical formulations was measured directly, in
triplicate, with a HI 99161 pH-meter (Hanna Instruments, Woonsocket,
Rhode Island, USA) calibrated before each measurement. The pH
readings were done in triplicate to ensure reproducibility.
2.7. Statistical analysis
For all the experiments three samples were analysed and all the
assays were carried out in triplicate. The results are expressed as mean
values ± standard deviation (SD). The differences between the dif-
ferent samples were analysed using one-way analysis of variance
(ANOVA) followed by Tukey's honestly significant difference post hoc
test with α=0.05, coupled with Welch's statistic. This treatment was
carried out using SPSS v. 22.0 program.
3. Results and discussion
3.1. Bioactive properties of the individual compounds
In the present work, the potential of the studied compounds to
suppress NO production was evaluated (Table 1a). Regarding the re-
sults, p-coumaric acid showed the highest potential presenting the
lowest EC50 values (152.17 ± 6.22 μg/mL), followed by cinnamic
(180.12 ± 14.18 μg/mL), protocatechuic (182.16 ± 9.76 μg/mL) and
p-hydroxybenzoic acids (195.21 ± 8.70 μg/mL). These results are in
agreement with the ones reported previously by our research group for
cinnamic and p-hydroxybenzoic acids [14]. On the other hand, ergos-
terol showed lower activity (338 ± 23 μg/mL), possibly due to its low
solubility in the culture medium. To our best knowledge, only Kuo et al.
[23] have reported an anti-inflammatory potential for commercial er-
gosterol at 10 μg/mL by inhibiting NO production in RAW. 7 macro-
phage cells.
Concerning the anti-tyrosinase activity (Table 1a), cinnamic acid
displayed the strongest activity exhibiting the lowest EC50 value
(0.31 ± 0.05mg/mL). The other tested compounds, showing EC50
values above the highest tested concentration of 2.0mg/mL, presented
limited activity. To the author's best knowledge, no studies have been
previously reported for the tyrosinase inhibitory activity of proto-
catechuic, p-hydroxybenzoic and cinnamic acids; however, some other
phenolic acids such as caffeic acid (43.09 ± 2.3 μM), ferulic acid
(51.85 ± 1.7 μM) and gallic acid (18.30 μM) have been reported as
significantly suppress tyrosinase activity [7,24]. Although in the pre-
sent study it was not possible to report anti-tyrosinase activity for p-
coumaric acid, studies conducted by An et al. [25] related that p-cou-
maric acid at 10 μg/mL showed activity at levels comparable to kojic
acid, whereas Jun et al. [26] confirmed that the anti-tyrosinase activity
mechanism of p-coumaric acid was due to its ability to reduce micro-
phthalmia-associated transcription factor (MITF) and tyrosinase mRNA
expression by 73 and 82%, respectively. The results show that these
compounds display a promising potential to be used, either alone or in
combination with other bioactive ingredients, to provide protection
against hyperpigmentation.
The results for the antimicrobial activity expressed as MIC values
are shown in Table 1b for the studied compounds. All the individual
compounds showed considerable antimicrobial capacity against gram
positive, gram negative bacteria and Candida, with cinnamic acid and
ergosterol exhibiting a similar antimicrobial pattern. Interestingly, p-
coumaric and protocatechuic acids presented the highest activity
against methicillin sensitive Staphylococcus aureus (SA), similarly to
what was reported by Parkar et al. [27]. All the compounds showed
inhibitory activity against E. coli in accordance with the results reported
by Cueva et al. [28]. Due to the well-known constraints associated with
the use of synthetic antimicrobial agents, this study highlights the po-
tential of the studied polyphenols and sterols as viable alternatives.
Phenolic acids such as ferulic and caffeic acid have been reported to be
interesting anti-wrinkling and photoprotective ingredients for skin care
products, as reported by Pluemsamran et al. [29], while Seok and Boo
[30] have reported anti-ageing potential for p-coumaric acid in dermal
fibroblasts cell lines. However, most of the cosmeceutical properties
were only evaluated for the individual compounds, and the compounds
seldom incorporated in base creams to evaluate if the bioactive prop-
erties are maintained.
3.2. Morphology and characteristics of the developed microspheres
The surface morphology of the prepared microspheres, visualised by
optical microscopy, right after preparation, and at magnifications of
Table 1a
Anti-inflammatory and anti-tyrosinase activities of the individual compounds.
Individual compounds Anti-inflammatory activity
(EC50 values, μg/mL)
Anti-tyrosinase activity
(EC50 values, mg/mL)
Cinnamic acid 180 ± 14c 0.31 ± 0.05⁎
Protocatechuic acid 182 ± 10c >2.0
p-Hydroxybenzoic acid 195 ± 9b 1.86 ± 0.01⁎
p-Coumaric acid 152 ± 6d >2.0
Ergosterol 338 ± 23a >2.0
Anti-inflammatory activity is expressed as EC50 values corresponding to 50% of
inhibition of the NO production in comparison with the negative control (100%
of NO production). Dexamethasone (positive control) EC50 values: 16 μg/mL.
Anti-tyrosinase activity is expressed as EC50 values corresponding to 50% of
inhibition of tyrosinase. Ascorbic acid (positive control) EC50 values: 31 μg/mL.
In the column different letters mean significant differences (p < 0.05).
⁎ Statistically different values, Student's t-test p-value< 0.001.
O. Taofiq, et al. Microchemical Journal 147 (2019) 469–477
472
40×, 100× and 400×, is shown in Fig. 1a. It is possible to observe a
consistent spherical morphology with particles of various sizes showing
no agglomeration. The lyophilized microspheres were rehydrated in
distilled water and analysed using the optical microscope at a magni-
fication of 100×. The final shape of the rehydrated microspheres was
quite irregular, but close to what was observed with microspheres right
after the encapsulation process.
The results for the particle size distribution, in number and volume,
represented as percentiles (D10, D50 and D90), are presented in
Table 2. From the analysis of particle size distribution (Fig. 1b), un-
imodal distributions in number can be depicted, whereas the distribu-
tions in volume were bimodal. Another important parameter to con-
sider is the Span (dispersity) which gives an indication of the particle
size distribution width and gives an indication of the dispersion of the
particle size distribution, i.e. of the size homogeneity of the produced
microparticles. From the obtained data, there is no significant dissim-
ilarity among the particles incorporating the various bioactive in-
gredients; only the empty microspheres showed a significant variation
(higher particle size distribution).
Table 2 summarizes the results obtained for the encapsulation yield,
loading, and efficiency of the produced alginate microspheres. To de-
termine EE %, the concentration of the analysed compounds was de-
termined both in the coagulation and washing solutions, and the
amount effectively encapsulated obtained by difference. The results
showed that the compounds were successfully encapsulated with EE
% > 50% for all the studied cases. The EY %, which represents the
weight of dry microspheres, recovered after encapsulation process, re-
latively to the weight of raw-materials initially use, was found to be
over 45% in all the samples. These values are quite satisfactory con-
sidering that the applied technique was conducted at a laboratory scale.
Some authors reported the encapsulation of phenolic acids such as
caffeic, chlorogenic and rosmarinic acids, using similar scales, with a
EY % only over 37%, for all the studied cases [31]. The EL%, re-
presenting the compound content per gram of microspheres, allows the
determination of the microsphere's amount needed to be incorporated
in the semi solid base creams. By analysing the results listed in Table 2,
the EL % was above 5% in all the cases.
Table 1b
Antimicrobial activity of the individual compounds.
Bacterial strains MIC (mg/mL)
Cinnamic acid p-Hydroxybenzoic acid p-Coumaric acid Protocatechuic acid Ergosterol
Gram+ MRSA 1 1 0.5 2.5 1
MSSA 1 1 0.5 2.5 1
E. faecalis 1 1 1 1 1
Gram− E. coli 1 1 2.5 0.25 1
P. mirabilis 1 2.5 2.5 2.5 1
Yeast strain
C. albicans 2.5 2.5 2.5 2.5 2.5
40x 400x 100x 100x lyophylised a
b
Fig. 1. a. Optical microscopy analysis with magnifications of 40, 100 and 400× of the microspheres after 4 h of coagulation under stirring.
b. Microparticles size distribution in number and volume.
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3.3. Bioactive properties of cosmeceutical formulations
In the present work, the cosmeceutical potential of each prepared
formulation was investigated based on their ability to display anti-in-
flammatory, anti-tyrosinase and antimicrobial activities. The results for
the in vitro anti-tyrosinase activity of the prepared cosmeceutical for-
mulations containing the individual compounds are presented in
Table 2. From the results, all the developed formulations (CFHA,
CFCoA, CFCA, CFPA) were able to inhibit tyrosinase activity over
6months under storage. On the other hand, the formulation prepared
with ergosterol (CFE) was also able to inhibit the tyrosinase activity,
however, a significant loss was observed as the storage time increased,
which can be attributed to the interaction between ergosterol and other
ingredients present in the base cream (Table 3a). Several studies have
reported that phenolic acids and related compounds are the most sig-
nificant contributors to anti-tyrosinase activity, but most of these stu-
dies only investigated pure compounds without perform their in-
corporation in topical semi-solid formulations [3,32]. An exception was
the work of Seo et al. [33], who conducted clinical trials by exposing
the forearms of 21 persons after topical application of a p-coumaric
acid-based cream twice daily. The results showed that there was a
significant improvement in the hyperpigmentation formation.
For the anti-inflammatory activity, all the developed formulations
containing the individual phenolic acids, cinnamic acid and ergosterol
were able to inhibit NO production (Table 3a). As observed for the
other bioactive properties there was a gradual loss of bioactivity as the
storage time increased, with the ergosterol-based formulation (CFE)
showing the lower anti-inflammatory activity. The formulation pre-
pared with p-coumaric acid (CFCoA) was the most promising one, as
determined based on the observations made with the individual com-
pounds.
The antimicrobial activity of the developed cosmeceutical for-
mulations, against gram negative, gram positive and yeast microbial
strains, are presented in Tables 3a and 3b. In all the cases, the prepared
formulations were found to be effective against Gram negative, Gram
positive bacteria and C. albicans. The antimicrobial activity of the for-
mulations incorporated with the free individual agents decreased along
the storage time, probably due to the interaction with the ingredients
present in the base cream. Our findings suggest that these bioactive
compounds have the potential to be used as preservatives capable of
preventing microbial contamination in cosmeceutical formulations.
The identification and quantification of the individual compounds
present in the prepared formulations, determined by HPLC, are pre-
sented in Table 3a. It can be concluded that all the target compounds
were stable and where identified in their corresponding base cream
formulation. The validation of an extraction protocol for phenolic acids
extraction from semi-solid formulation still poses some challenges.
However, it was possible to effectively identify and quantify the amount
of phenolic acids and related compounds present in each prepared
cosmeceutical formulation over the storage time. The results showed
that there was no significant loss of phenolic compounds, or ergosterol,
over the course of incubation period for all the considered semi-solid
formulations.
Table 2
Particle size distribution in number and volume (D10, D50 and D90 and mean particle size), encapsulation efficiency, load and yield of the prepared microspheres.
Samples EE (%) EY (%) EL (%) Particle size distribution (μm) Mean particle size (μm)
Volume distribution Number distribution Number Volume
D10 D50 D90 Span D10 D50 D90
A na 60.2 na 19.5 79.2 235 2.72 0.82 1.15 2.83 1.50 102
B 88.3 57.8 9.80 20.5 74.6 206 2.28 0.72 0.93 2.10 1.63 94.5
C 73.7 55.7 8.19 25.4 90.7 208 2.01 0.71 0.91 1.84 1.07 104
D 98.4 58.9 10.9 36.1 115 261 1.95 0.72 0.91 1.95 1.10 132
E 50.3 62.2 5.59 21.3 71.0 186 2.31 0.72 0.95 2.05 1.15 90.0
F 63.2 45.5 7.02 36.3 108 273 2.19 0.63 0.77 1.26 0.86 132
na-not applied; A - empty microparticles B - p-hydroxycinnamic acid, C - p-coumaric acid, D - cinnamic acid, E - protocatechuic acid, F - ergosterol.
Table 3a
Bioactive properties of the individual compounds, developed cosmeceutical formulations and compounds monitoring over the storage time.
Creams Anti-tyrosinase activity (EC50 values, mg/mL) Anti-inflammatory activity (EC50 values, mg/mL) Bioactive compounds profile (mg/g)
Time 0 Time 3 Time 6 Time 0 Time 3 Time 6 Time 0 Time 3 Time 6
CFHA 54 ± 4b 55.3 ± 0.1 b 59.9 ± 0.5a 30.66 ± 1c 41.92 ± 2.17 b 54.13 ± 0.93a 6.80 ± 0.07a 6.83 ± 0.04a 6.39 ± 0.02b
CFCoA 37.6 ± 0.9b 41 ± 7 b 51 ± 6a 22.64 ± 0.76c 33.04 ± 1.51 b 45.29 ± 1.63a 6.67 ± 0.03a 6.52 ± 0.08 b 6.48 ± 0.07b
CFCA 32.3 ± 0.2b 36 ± 5ab 40 ± 3a 33.47 ± 0.46c 40.03 ± 1.09 b 47.05 ± 1.01a 6.50 ± 0.01a 6.4 ± 0.2a 6.39 ± 0.02a
CFPA 40 ± 3b 43 ± 2b 61 ± 7a 36.28 ± 1.62⁎ 47.59 ± 0.55⁎ >60 6.64 ± 0.08a 6.5 ± 0.1b 6.42 ± 0.01b
CFE 24 ± 2c 51 ± 5 b 98.2 ± 0.7a 53.35 ± 1.62 > 60 >60 6.9 ± 0.01a 6.81 ± 0.01b 6.78 ± 0.02b
CFEM >100 >100 >100 >60 >60 >60 nd nd nd
CFMHA >100 >100 48 ± 12 >60 50.56 ± 0.57⁎ 42.66 ± 0.94⁎ nd nd nd
CFMCoA >100 73 ± 1⁎ 45 ± 4⁎ >60 42.34 ± 1.02⁎ 34.57 ± 0.43⁎ nd nd nd
CFMCA >100 80.8 ± 0.7⁎ 43.0 ± 0.8⁎ >60 48.440.5 ± ⁎ 40.33 ± 1.13⁎ nd nd nd
CFMPA >100 >100 49 ± 8 >60 46.99 ± 1.43⁎ 40.07 ± 0.17⁎ nd nd nd
CFME >100 47 ± 4⁎ 32.6 ± 0.6⁎ >60 >60 >60 nd nd nd
BA >100 >100 >100 >60 >60 >60 nd nd nd
nd-not determined, for easy identification of the samples, each formulation was labelled as follows: i) Cosmeceutical formulations incorporated with free Individual
compounds: CFHA - p-hydroxybenzoic acid, CFCoA - p-coumaric acid, CFCA - cinnamic acid, CFPA - protocatechuic acid, CFE - ergosterol; ii) cosmeceutical for-
mulations incorporated with microencapsulated compounds: CFEM - empty microspheres (control), CFMHA - microspheres with p-hydroxybenzoic acid, CFMCoA -
microspheres with p-coumaric acid, CFMCA - microspheres with cinnamic acid, CFMPA - microspheres with protocatechuic acid, CFME - microspheres with er-
gosterol. For all the assays a negative control was analysed with base cream (BA). In each row different letters mean significant differences (p < 0.05).
⁎ Statistically different values, Student's t-test p-value< 0.001.
O. Taofiq, et al. Microchemical Journal 147 (2019) 469–477
474
3.4. Real time in vitro release
Real time in vitro release of the bioactive compounds from a poly-
meric microsphere is typically conducted to evaluate the control release
at appropriate environmental and physiological conditions. Sometimes
the release may take weeks, months, or even years [34]. The real time
in vitro release of the microencapsulated bioactive agents was per-
formed under controlled temperature medium. Their release was eval-
uated based on their potential to increase the bioactive properties of the
corresponding formulations. From the obtained data, microspheres
showed a very slow release of the encapsulated bioactives up to the 6th
month under storage. Throughout the process of microencapsulation,
the anti-tyrosinase, anti-inflammatory and antimicrobial activities were
not compromised since the bioactivity was kept in almost all cases,
highlighting the potential of alginate particles as effective delivery
vehicles. Regarding the anti-tyrosinase activity, a fast release, sufficient
to cause activity, was achieved for the formulations at the 3rd month of
storage as shown by the data of Tables 3a and 3b. It was also observed
that both formulations CFMCoA and CFMCA showed similar profile
relative to the anti-tyrosinase and anti-inflammatory activity. The re-
lease in both cases was able to sustain the bioactivities up to the 6th
month. As expected BCEM did not show any contribution to the tested
bioactivities. CFMPA and CFMHA were able to maintain an anti-tyr-
osinase activity lower than the one obtained for CFMCoA and CFMCA,
regardless they showed the best anti-inflammatory activity. BCE was
able to sustain the anti-tyrosinase activity, however no anti-in-
flammatory activity was perceived. The slow release supports the
suitability of the microencapsulation process to be used in the design of
cosmeceutical formulations, whose shelf life span from months to even
years, making the gradual release adequate to ensure the continuous
effectiveness against microbial growth. It is also interesting to note that
the compounds not released during the evaluated storage time can be
further released in the skin during the application of the cosmeceutical
formulation. In fact, due to the applied pressure, capsules breakage will
occur with subsequent release of the encapsulated compounds, which
will result in skin benefits derived from the fraction of preserved
bioactives. From the obtained results, the alginate microcapsules
showed potential to ensure controlled release of the bioactive agents,
which will add in the cosmetic preservation during storage, and will
provide benefits for the skin upon application (preserved fraction).
Some relevant reports have been presented on the use of micro-
encapsulation techniques to protect bioactive compounds for cosme-
ceutical purposes. Biswick et al. [35], microencapsulated caffeic acid,
with the produced microparticles able to withstand both UVA and UVB
radiation, indicating their suitability to be used in the design of
sunscreen cosmetic formulations. Ouimet et al. [36] microencapsulated
ferulic acid, whose slow release was reported as acting for days, but
able to achieve antioxidant activity. Different factors such as polymer
nature and molecular weight, and microparticle's size have been re-
ported by Sharma et al. [37], as influencing the release rate making
these issues worth of further investigation. Some studies report an ac-
celerated release under different conditions such as temperature, sol-
vent, pH, enzymes effect or even due to stirring rate [38]. However,
some of these conditions do not mimic the real environment, thus the
real release mechanism, making the studies performed under the con-
text of the present work valuable tools to access the long-lasting effect
of the encapsulated bioactive compounds. The overall results show that
microencapsulation can provide efficient tools to support the develop-
ment of cosmetic formulations promoting the preservation of the cos-
meceutical ingredients, and the sustained release of the compounds (i.e.
bioactivity maintenance).
3.5. Physicochemical parameters
Although it is possible to find in the market, a wide range of cos-
metic colours, the majority of consumers still prefer products with the
basic white colour. Hence, the cosmetic industry has paid attention to
colour management during the design of new products. Responding to
this requisite, the physicochemical evaluation of the prepared semisolid
formulations in terms of colour, and also pH, was carried out during the
storage period at time 0, 3 and 6months (Table 4). Over the course of
the six-month incubation period, no significant colour changes were
observed, suggesting that the individual compounds are stable, and
their degradation does not lead to end products causing significant
colour changes. It was possible to observe that the formulations pre-
sented lower levels of lightness (l*) as the storage time increase, which
may be derived from the oxidation of the incorporated compounds.
Lower l* values and higher yellowness (b⁎) was observed for the for-
mulations prepared with the individual compounds, whereas the colour
coordinates for the formulations prepared with the microspheres re-
vealed a deeper red (greater a* value), mainly due to the contribution
of alginate. Overall, the initial odour (qualitative evaluation) and
colour were maintained, i.e. they were not significantly different over
the course of the storage time, which are crucial parameters for the
preliminary analysis of stability.
The rate of dermal absorption of topical formulations, such as lo-
tions and creams, are often influenced by the product pH. The skin
surface pH is around 5.5, and at this condition, the skin micro-flora,
barrier homeostasis and stratum corneum are maintained [39,40]. Sev-
eral reports have suggested that a pH between 3.5 and 6.5 can be
Table 3b
Antimicrobial activity of the final cosmeceutical formulations.
Samples Mic (mg/mL)
Bacterial strains Yeast
E. faecalis MSSA MRSA E. coli P. mirabilis C. albicans
T0 T3 T6 T0 T3 T6 T0 T3 T6 T0 T3 T6 T0 T3 T6 T0 T3 T6
BA >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400
CFHA 200 200 400 200 200 400 200 200 400 200 200 400 400 400 400 400 400 400
CFCoA 200 200 400 100 100 200 100 100 200 400 400 400 200 200 400 400 400 400
CFCA 200 200 400 200 200 400 200 200 400 200 200 400 200 200 400 400 400 400
CFPA 200 200 400 100 100 200 100 100 200 400 400 400 400 400 400 400 400 400
CFE 200 200 400 200 200 400 200 200 400 200 200 400 200 200 400 400 400 400
CFEM >400 >400 >400 >400 400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400 >400
CFMHA >400 400 200 >400 400 200 >400 400 200 >400 400 200 >400 >400 400 >400 >400 400
CFMCoA >400 400 200 >400 200 >400 >400 200 100 >400 >400 400 >400 >400 200 >400 >400 >400
CFMCA >400 400 200 >400 400 200 >400 400 200 >400 >400 400 >400 >400 400 >400 >400 >400
CFMPA >400 400 200 >400 200 100 >400 200 100 >400 >400 400 >400 >400 400 >400 >400 >400
CFME >400 400 200 >400 400 200 >400 400 200 >400 >400 400 >400 >400 400 >400 >400 400
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considered suitable for cosmetic formulations since most of the patho-
genic bacteria, such as S. aureus, thrive best at neutral pH levels [39]. In
this work, all the developed cosmeceutical formulations presented a pH
in the range 3.4–6.0, suggesting that they have a favourable pH along
the storage time. The samples, stored at 4 °C in darkness, presented no
significant pH variation, which is a clear indication of their stability.
Also, most of the products exhibited excellent stability under this
temperature.
4. Conclusion
Several bioactive compounds have shown relevant cosmeceutical
properties, essential to maintain skin health. In this context, devel-
oping delivery systems to allow their sustained release is a strategy of
high importance in order to take full advantage of their benefits. The
findings achieved in this work reveal that the studied compounds (p-
hydroxybenzoic, p-coumaric, protocatechuic and cinnamic acids, and
ergosterol) displayed anti-tyrosinase, antimicrobial and anti-in-
flammatory activities making them suitable to be explored as multi-
functional cosmeceutical ingredients. The atomization/coagulation
technique was successfully applied to encapsulate the bioactive
agents, conducting to EE% values above 50% for all the tested com-
pounds. After incorporating the individual compounds in the cosmetic
formulations, bioactive properties were only partially maintained
while their microencapsulated formulations have shown a sustained
release able to better preserve bioactivity. Moreover, over the course
of storage time, no significant changes were observed in the tested
stability parameters, namely colour and pH. By the obtained results,
the analysed bioactive agents revealed promising bioactivity and
stability. Studies related with the in vitro skin permeation using cell-
based models to determine topical bioavailability and confirm the
absence of cytotoxic effects in fibroblast or keratinocyte cell lines, will
the next steps going forward.
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